1991 - 1999

1999

• Stable expression of HIV-1 Nef induces changes in growth properties and activation state of human astrocytes. (online-abstract)
  Kohleisen B., Shumay E., Sutter G., Förster R., Brack-Werner R., Nuesse M., Erfle V., 13, 2331-2341, (1999)
• An anti-HIV strategy combining chemotherapy and therapeutic vaccination. (online-abstract)
  Rosenwirth B., Bogers W., Nieuwenhuis I., ten Haaft P., Niphuis H., Kuhn E., Bischofsberger N., Erfle V., Sutter G., Berglund P., Liljeström P., Überla K., Heeney J.
  J. Med. Primatol., 28, 195-205 (1999)
• Modified vaccinia virus Ankara for delivery of tyrosinase as melanoma-associated antigen: Induction of tyrosinase- and melanoma-specific human leukocyte antigen-A*0201-restricted cytotoxic T cells in vitro and in vivo. (pdf, 631 KB)
  Drexler I., Antunes E., Schmitz M., Wölfel T., Huber C., Erfle V., Rieber P., Theobald M., Sutter G.
  Cancer Res., 59, 4955-4963 (1999)
• Vaccination with Rev and Tat against AIDS. (online-abstract)
  Osterhaus A., van Baalen C., Schutten M., Gruters R., Siebelink C., Hulskotte E., Tijhaar E., van Amerong G., Fleuchaus A., Erfle V.,Sutter G.
  Vaccine, 17, 2713-2714 (1999)
• Feline calcivirus capsid protein expression and capsid assembly in cultured feline cells. (pdf, 907 KB)
  Geissler K., Schneider K., Fleuchaus A., Parrish C., Sutter G., Truyen U.
  J. Virol., 73, 834-838 (1999)

1998

• Gene transfer into human dentric antigen-presenting cells by vaccinia virus and adenovirus vectors. (online-abstract)
  DiNicola M., Siena S., Bregni M., Longoni P., Magni M., Milanesi M., Matteucci P., Mortarini R., Anichini A., Parmiani G., Drexler I., Erfle V., Sutter G., Gianni A.M.
  Cancer Gene Ther., 5, 350-356 (1998)
• Serp2, an inhibitor of the interleukin-1 ß converting enzyme, is critical in the pathobiology of myxoma virus. (pdf, 1,2 MB)
  Messud-Petit F., Gelfi J., Delverdier M., Amardeih M., Py R., Sutter G., Bertagnoli S.
  J. Virol., 72, 7830-7839 (1998)
• Highly attenuated modified vaccinia virus Ankara (MVA) replicates in baby hamster kidney cells (BHK), a potential host for virus propagation, but not in various human transformed and primary cells. (pdf, 373 KB)
  Drexler I., Heller K., Wahren B., Erfle V., Sutter G.
  J. Gen. Virol., 79, 347-352 (1998)

1997

• Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. (pdf, 629 KB)
  Hinkula J., Svanholm C., Kohleisen B., Erfle V., Okuda K., Wigzell H., Wahren H.
  J. Virol., 71, 5528-5530 (1997)
• Rescue of measles virus using a replication-deficient vaccinia-T7 vector. (online-abstract)
  Schneider H., Spielhofer P., Kaelin K., Dötsch C., Radeck F., Sutter G., Billeter M.
  J. Virol. Meth., 64, 57-64 (1997)

1996

• Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified virus Ankara. (pdf, 720 KB)
  Hirsch v., Fuerst T., Sutter G., Carroll M., Yang L., Goldstein S., Piatak M., Elkins W., Montefiori D., Moss B.,
  Lifson J.
  J. Virol. , 70, 3741-3752 (1996)

1995

• In-situ amplification of measles virus RNA by self sustained sequence replication (3SR) reaction. (online-abstract)
  Höfler H., Pütz B., Mueller J., Neubert W., Sutter G., Gais P.
  Lab. Invest., 73, 577-585 (1995)
• Non-replicating vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase. (online-abstract)
  Sutter G., Ohlmann M., Erfle V.
  FEBS Lett., 371, 9-12 (1995)
• Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. (online-abstract)
  Sutter G., Moss B.
  Dev. Biol. Stand., 84, 195-200 (1995)

1994

• A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity to influenza virus. (online-abstract)
  Sutter G., Wyatt L., Foley P., Bennink J., Moss B.
  Vaccine, 12, 1032-1040 (1994)
• Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant. (pdf, 1,80 MB)
  Sutter G., Ramsey-Ewing A., Rosales R., Moss B.
  J. Virol., 68, 4109-4116 (1994)
• A cellular factor is required for transcription of vaccinia viral intermediate-stage genes. (pdf, 2,57 MB)
  Rosales R., Sutter G., Moss B.
  PNAS USA, 91, 3794-3798 (1994)

1992

• Nonreplicating vaccinia vector efficiently expresses recombinant genes. (pdf, 2,25 MB)
  Sutter G., Moss B.
  PNAS USA, 89, 10847-10851 (1992)

1991

• Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virule nce.(pdf, 2,83 MB)
  Meyer H., Sutter G., Mayr A.
  J. Gen. Virol., 72, 1031-1038 (1991)